J&J Plans 10 Potential Blockbuster Filings By 2023
Executive Summary
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
You may also be interested in...
No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025
Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.
J&J US Pharma Sales Under Pressure From Pricing And Generics
A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in the second quarter.
US Product Launches To Plan For In 2020
A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.